A Chemist’s Journey from the Battlefield to Biopharma Leadership
Dave Williamson leads innovations at Abzena, focusing on bioconjugates and ADCs to transform patient care globally. His diverse experiences, from the U.S. Army to pharmaceutical technology, fuel his passion for…
The Unseen Revolution at Abzena: How One Man’s Journey is Accelerating Pharma Innovation
Abzena's global facilities are hubs of innovation in pharmaceutical development, led by CIO Dave Williamson. Williamson's diverse background, from the US Army to biotechnology, informs his approach to bioconjugate and…
The Surprising New Frontier for Biotech: Drug Discovery in Space
Exobiosphere, a Luxembourg-based company, is pioneering systematic drug discovery in space, leveraging €2 million in seed funding and support from the Luxembourg Space Agency. In microgravity, proteins crystallize more uniformly,…
How the Final Frontier Could Revolutionize Biotech as We Know It
Space and biotechnology are converging to revolutionize drug discovery and disease research through microgravity experimentation. Protein crystals grown in space offer enhanced insights for drug design, potentially leading to groundbreaking…
Biotech’s Galactic Leap: How Microgravity is Transforming Drug Discovery
Microgravity in space enhances biotech innovation, aiding drug discovery and disease research, particularly in oncology and chronic diseases. Luxembourg-based Exobiosphere leverages microgravity for drug discovery with €2 million in funding,…
Unlocking the Future of Medicine: The New Alliance Transforming mRNA Therapeutics
Wacker Biotech and RNAV8 Bio are collaborating to revolutionize mRNA-based therapies. Wacker Biotech brings expertise in pDNA/mRNA manufacturing and lipid nanoparticle (LNP) formulation. RNAV8 Bio specializes in optimizing noncoding mRNA…
Revolutionizing mRNA Therapy: A New Partnership Aims to Transform Biopharma Industry
A strategic partnership between Wacker Biotech and RNAV8 Bio aims to revolutionize mRNA-based therapies. The collaboration focuses on optimizing untranslated regions (UTRs) in mRNA strands to enhance drug effectiveness. Improved…
How Chinese Biotech Titans Are Quietly Revolutionizing Global Pharmaceutical Collaborations
Chinese biotech firms are reshaping the global pharmaceutical landscape with significant international collaborations. In the first quarter, 33 deals worth US$36.2 billion were established, marking an 18% increase from the…
A Groundbreaking Partnership: Revolutionizing mRNA Therapy Development
Wacker Biotech partners with RNAV8 Bio to advance mRNA-based therapies, enhancing the biopharmaceutical landscape. The collaboration leverages Wacker's expertise in pDNA, mRNA production, and LNP formulation with RNAV8's mRNA engineering,…
The Surge of Chinese Biotech: What’s Fueling These High-Value Global Deals?
Chinese biotech companies are actively expanding internationally, increasing overseas collaborations by 18% in the first quarter. The companies have sealed 33 international partnerships, totaling $36.2 billion in transactions, showcasing their…